After coculturing sPD-1 with tumor cells (H22 cell line) and spleen lymphocytes, the group demonstrated a dual effect of sPD-1: an enhancement of the immune response through interaction with immune cells such as DCs and a blockade of PD-L1 on tumor cells [27]. Here, HOXD13 is linked to neoplasm.